Follicular Phase Cycle Programming Using Estradiol in Oocyte Donors-a Convenient and Effective Approach

Overview

Journal F S Rep

Specialty Reproductive Medicine

Date 2022 Apr 7

PMID 35386503

Authors

Manish Banker

Parul Arora

Jwal Banker

Reena Gupta

Sandeep Shah

Affiliations

Soon will be listed here.

Abstract

Objective: To study the efficacy of estradiol for cycle programming in oocyte donors when administered in the follicular phase only.

Design: Prospective interventional study.

Setting: Single fertility center.

Patients: Ninety-three oocyte donors underwent programmed stimulation using estradiol in the follicular phase. Their previous unprogrammed cycles were used as historical controls.

Interventions: Donors received 8 mg of estradiol hemihydrate from day 2 till 1 day before the start of stimulation.

Main Outcome Measures: The primary outcome measures studied were the number of oocytes retrieved, duration of stimulation, and total gonadotropin dose. The number of mature oocytes, oocyte maturation rate, fertilization rate, blastulation rate, implantation rate, and pregnancy rate were the secondary outcomes.

Results: The average number of oocytes retrieved was higher in the study group (36.4 vs. 32.5). The duration of stimulation (9.22 vs. 9.21 days) and the total gonadotropin dose were similar (3,085.5 vs. 3,026 IU) between both groups. The mean number of mature oocytes retrieved was higher in the study group (30.1 vs. 26.3), but the maturation rate was similar (84.6% vs. 81.2%). The fertilization rate (77.8% vs. 78.7%), number of blastocysts, blastulation rate (32.7% vs. 33.2%), implantation rate (59.3% vs. 66.3%), and pregnancy rate (77.3% vs. 77.1%) showed no statistically significant difference.

Conclusions: Estradiol usage in the follicular phase alone is an effective and convenient option for cycle programming in oocyte donors. It can yield similar mature oocytes and does not affect the clinical outcomes. Further larger sample-sized studies may be needed to validate its use which can also be extended to routine in vitro fertilization cycles.

Clinical Trials Registration Number: CTRI/2020/09/027815.

Citing Articles

Reply of the Authors: Follicular phase estradiol administration can be the easiest way of cycle scheduling and follicular synchronization.

Banker M, Arora P, Banker J, Gupta R, Shah S F S Rep. 2022; 3(2):176.

PMID: 35789725 PMC: 9250138. DOI: 10.1016/j.xfre.2022.04.006.

Follicular phase estradiol administration can be the easiest way of cycle scheduling and follicular synchronization.

Ata B, Turkgeldi E, Yildiz S, Angun B, Urman B F S Rep. 2022; 3(2):175.

PMID: 35789716 PMC: 9250137. DOI: 10.1016/j.xfre.2022.03.007.

Another option for cycle programming: follicular start estradiol in oocyte donation cycles.

Quinn M F S Rep. 2022; 3(1):10.

PMID: 35386505 PMC: 8978108. DOI: 10.1016/j.xfre.2022.01.003.

References

Farquhar C, Rombauts L, Kremer J, Lethaby A, Ayeleke R . Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev. 2017; 5:CD006109. PMC: 6481489. DOI: 10.1002/14651858.CD006109.pub3. View

Aslan K, Avci B, Uncu G, Saribal S, Ata B . Scheduling GnRH antagonist cycles by a short course of oral estradiol administration during early follicular phase: a comparative study with non-scheduled cycles. Gynecol Endocrinol. 2015; 31(6):465-8. DOI: 10.3109/09513590.2015.1006189. View

Banker M, Dyer S, Chambers G, Ishihara O, Kupka M, de Mouzon J . International Committee for Monitoring Assisted Reproductive Technologies (ICMART): world report on assisted reproductive technologies, 2013. Fertil Steril. 2021; 116(3):741-756. DOI: 10.1016/j.fertnstert.2021.03.039. View

Alberta H, Berry R, Levine A . Risk disclosure and the recruitment of oocyte donors: are advertisers telling the full story?. J Law Med Ethics. 2014; 42(2):232-43. DOI: 10.1111/jlme.12138. View

Quigley M, Collins R, Schover L . Establishment of an oocyte donor program. Donor screening and selection. Ann N Y Acad Sci. 1991; 626:445-51. DOI: 10.1111/j.1749-6632.1991.tb37936.x. View

Cedrin-Durnerin I, Guivarch-Leveque A, Hugues J . Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012; 97(6):1359-64.e1. DOI: 10.1016/j.fertnstert.2012.02.028. View

Verberg M, Eijkemans M, Heijnen E, Broekmans F, de Klerk C, Fauser B . Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod. 2008; 23(9):2050-5. DOI: 10.1093/humrep/den219. View

Hauzman E, Zapata A, Bermejo A, Iglesias C, Pellicer A, Garcia-Velasco J . Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod Biol Endocrinol. 2013; 11:96. PMC: 3849807. DOI: 10.1186/1477-7827-11-96. View

Baerwald A, Pierson R . Ovarian follicular waves during the menstrual cycle: physiologic insights into novel approaches for ovarian stimulation. Fertil Steril. 2020; 114(3):443-457. DOI: 10.1016/j.fertnstert.2020.07.008. View

10.

Popovic-Todorovic B, Santos-Ribeiro S, Drakopoulos P, De Vos M, Racca A, Mackens S . Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Hum Reprod. 2019; 34(10):2027-2035. DOI: 10.1093/humrep/dez132. View

11.

De Ziegler D, Brioschi P, Benchaa C, Campana A, Ditesheim P, Fanchin R . Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction. Fertil Steril. 1999; 72(1):77-82. DOI: 10.1016/s0015-0282(99)00155-7. View

12.

Le Nestour E, Marraoui J, Lahlou N, Roger M, De Ziegler D, Bouchard P . Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. J Clin Endocrinol Metab. 1993; 77(2):439-42. DOI: 10.1210/jcem.77.2.8345049. View

13.

Thomas R, Halvorson L, Carr B, Doody K, Doody K . Efficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles. J Reprod Infertil. 2014; 14(4):207-13. PMC: 3911817. View

14.

Zegers-Hochschild F, Adamson G, Dyer S, Racowsky C, de Mouzon J, Sokol R . The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017; 108(3):393-406. DOI: 10.1016/j.fertnstert.2017.06.005. View

15.

Fanchin R, Cunha-Filho J, Schonauer L, Kadoch I, Cohen-Bacri P, Frydman R . Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril. 2003; 79(2):316-21. DOI: 10.1016/s0015-0282(02)04574-0. View

16.

Cedrin-Durnerin I, Bstandig B, Parneix I, Bied-Damon V, Avril C, Decanter C . Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2006; 22(1):109-16. DOI: 10.1093/humrep/del340. View

17.

Blockeel C, Engels S, De Vos M, Haentjens P, Polyzos N, Stoop D . Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reprod Biomed Online. 2012; 24(3):272-80. DOI: 10.1016/j.rbmo.2011.11.012. View

18.

Griesinger G, Kolibianakis E, Venetis C, Diedrich K, Tarlatzis B . Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril. 2010; 94(6):2382-4. DOI: 10.1016/j.fertnstert.2010.04.025. View

19.

Blockeel C, Riva A, De Vos M, Haentjens P, Devroey P . Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertil Steril. 2011; 95(5):1714-9.e1-2. DOI: 10.1016/j.fertnstert.2011.01.028. View